These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 2345577)

  • 1. ['New wine in old bottles'; therapy for Parkinson disease using subcutaneous apomorphine].
    Jansen EN; van Laar T
    Ned Tijdschr Geneeskd; 1990 May; 134(18):889-91. PubMed ID: 2345577
    [No Abstract]   [Full Text] [Related]  

  • 2. [Subcutaneous apomorphine infusion in the treatment of Parkinson disease].
    Albani C; Zangger I; Fischer G
    Schweiz Rundsch Med Prax; 1992 Aug; 81(35):1011-5. PubMed ID: 1410978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unexpected findings with apomorphine and their possible consequences.
    Cotzias GC; Mena I; Papavasiliou PS; Mendez J
    Adv Neurol; 1974; 5():295-9. PubMed ID: 4440577
    [No Abstract]   [Full Text] [Related]  

  • 4. Levodopa in the treatment of Parkinson's disease: current controversies.
    Gerlach M; Reichmann H; Riederer P
    Mov Disord; 2005 May; 20(5):643; author reply 643-4. PubMed ID: 15732130
    [No Abstract]   [Full Text] [Related]  

  • 5. Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: results of a two-year, prospective follow-up.
    Kanovský P; Kubová D; Bareš M; Hortová H; Streitová H; Rektor I; Znojil V
    Mov Disord; 2002 Jan; 17(1):188-91. PubMed ID: 11835461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Apomorphine for treatment of "off-periods" in Parkinson's disease].
    Zoldan J; Merims D; Kuritzky A; Ziv I; Melamed E
    Harefuah; 1999 Nov; 137(10):444-6, 512, 511. PubMed ID: 10959339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients.
    Manson AJ; Turner K; Lees AJ
    Mov Disord; 2002 Nov; 17(6):1235-41. PubMed ID: 12465062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges.
    Katzenschlager R; Hughes A; Evans A; Manson AJ; Hoffman M; Swinn L; Watt H; Bhatia K; Quinn N; Lees AJ
    Mov Disord; 2005 Feb; 20(2):151-7. PubMed ID: 15390035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apomorphine and diphasic dyskinesia.
    Durif F; Deffond D; Dordain G; Tournilhac M
    Clin Neuropharmacol; 1994 Feb; 17(1):99-102. PubMed ID: 8149366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
    Chen JJ; Obering C
    Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of apomorphine in clinical practice.
    MacMahon DG
    Adv Neurol; 1999; 80():529-33. PubMed ID: 10410767
    [No Abstract]   [Full Text] [Related]  

  • 12. [Long-term results of continuous subcutaneous apomorphine pump therapy in patients with advanced Parkinson disease].
    Kreczy-Kleedorfer B; Wagner M; Bösch S; Poewe W
    Nervenarzt; 1993 Apr; 64(4):221-5. PubMed ID: 8506009
    [No Abstract]   [Full Text] [Related]  

  • 13. Apomorphine: an underutilized therapy for Parkinson's disease.
    Poewe W; Wenning GK
    Mov Disord; 2000 Sep; 15(5):789-94. PubMed ID: 11009181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Fluctuations and dyskinesias as early L-dopa-induced motor complications in severe Parkinsonian's patients].
    Vaamonde J; Ibáñez R; Gudín M; Hernández A
    Neurologia; 2003 Apr; 18(3):162-5. PubMed ID: 12677484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transdermal apomorphine permeation from microemulsions: a new treatment in Parkinson's disease.
    Priano L; Albani G; Brioschi A; Calderoni S; Lopiano L; Rizzone M; Cavalli R; Gasco MR; Scaglione F; Fraschini F; Bergamasco B; Mauro A
    Mov Disord; 2004 Aug; 19(8):937-42. PubMed ID: 15300660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effect of apomorphine on the bladder of parkinsonian patients].
    Aranda B; Cramer P; Adba MA
    J Urol (Paris); 1992; 98(1):25-9. PubMed ID: 1527394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Shifting to subcutaneous infusion of apomorphine in advanced Parkinson's disease patients on an out-patient basis: experience and recommendations].
    Castaño B; Mateo D; Giménez-Roldán S
    Neurologia; 2007 Apr; 22(3):133-7. PubMed ID: 17364250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apomorphine for the acute treatment of "off" episodes in Parkinson's disease.
    Stacy M; Silver D
    Parkinsonism Relat Disord; 2008; 14(2):85-92. PubMed ID: 18083605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current controversies: levodopa in the treatment of Parkinson's disease.
    Sharma JC; Vassallo M; Ross IN
    Mov Disord; 2005 May; 20(5):642-3; author reply 643-4. PubMed ID: 15732129
    [No Abstract]   [Full Text] [Related]  

  • 20. [Subcutaneous apomorphine in the treatment of Parkinson's disease].
    Linazasoro G
    Neurologia; 1994 Jan; 9(1):1-3. PubMed ID: 8161461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.